HRV Global LifeSciences

What HRV Global LifeSciences does

HRV Global LifeSciences, operating commercially as HRV Pharma, is a privately held Indian pharmaceutical company founded in 2015 and headquartered in Hyderabad, Telangana. The company positions itself as India's first integrated virtual pharmaceutical company, sourcing and supplying Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, pellets, food additives, and orphan-drug/niche-therapeutic APIs to B2B customers across 50+ countries. Rather than owning manufacturing assets, HRV operates an asset-light model that integrates, manages, and scales a network of cGMP-certified production partners through a digital platform, claiming faster market entry for global pharmaceutical partners.

The company's technology stack centers on a virtual manufacturing platform that applies AI-driven demand forecasting and blockchain-based traceability to optimize supply chain operations across its partner network. A multi-year strategic partnership with Haleos Labs, announced in January 2026, is expected to deliver 5-7 new molecules annually targeting rare diseases, CNS disorders, and metabolic conditions. The company has set a strategic target of filing over 100 USDMFs and CEPs by 2028 and entering 30+ new markets through alliances and M&A, with planned expansion from APIs into Finished Dosage Forms (FDFs).

HRV's revenue model combines transaction-based API and formulation sales with professional services from contract development and manufacturing partnerships. Pricing is quote-based and not publicly disclosed. The company serves three primary segments: global pharmaceutical companies (orphan/niche APIs and FDFs), finished dosage form manufacturers (regulatory filings and global supply), and regional market players (market expansion support across US, EU, MENA, Latin America, and veterinary sectors). International operations are managed through NHG Pharma (New Horizon Global Pharma) and its subsidiaries in the USA, Lithuania, and the UAE, with additional offices in Switzerland and Turkey. The group has surpassed USD 50 million in revenue and was awarded an EcoVadis Bronze Medal for sustainability, placing it in the top 35% of companies assessed worldwide. Hari Kiran Chereddi serves as Managing Director.

Name

HRV Global LifeSciences

Legal name

HRV Global LifeSciences Pvt.Ltd

Website

https://hrvglobal.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

HRV Global LifeSciences (HRV Pharma) is a Hyderabad-based virtual pharmaceutical company that sources and supplies APIs, intermediates, and niche-therapeutic ingredients to B2B partners across 50+ countries through an asset-light network of cGMP-certified manufacturers, with planned expansion into Finished Dosage Forms.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Contract development manufacturing
• Virtual pharmaceutical platform
• Pharma intermediates supply
• Orphan drug APIs

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. API and Formulation Sales: Revenue generated from sale of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) to global pharmaceutical partners. The company leverages an asset-light model with cGMP-certified manufacturing partners to produce and supply pharmaceutical products across regulated and semi-regulated markets.
2. Contract Development and Manufacturing Services: Multi-year strategic partnership with Haleos Labs for end-to-end development services including route scouting, process intensification, scale-up, validation and global supply of orphan-drug and niche-therapeutic APIs. Expected 5 to 7 new molecules annually targeting rare diseases, CNS disorders and metabolic conditions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

HRV Global LifeSciences (HRV Pharma) operates as India's first integrated virtual pharmaceutical company, sourcing and supplying active pharmaceutical ingredients (APIs), orphan and niche-therapeutic APIs, and finished dosage forms through an asset-light model that integrates a global network of cGMP-certified manufacturing partners. The company combines a digital platform with regulatory-first execution to deliver pharmaceutical products to B2B customers across more than 50 countries.

Product overview

HRV Pharma operates as India's first integrated virtual pharmaceutical company, offering a platform-based model that connects global B2B customers with a network of cGMP-certified manufacturers. The core portfolio includes APIs and Orphan/Niche Therapeutic APIs, with plans to expand into Finished Dosage Forms (FDFs). The company provides digital services including AI-driven demand forecasting and blockchain-based traceability to optimize its virtual manufacturing supply chain. The offering combines an asset-light digital platform with regulatory-first execution to deliver critical pharmaceuticals worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• APIs (Active Pharmaceutical Ingredients) HRV Pharma sources and supplies critical Active Pharmaceutical Ingredients through its global network of cGMP-certified manufacturers, serving B2B partners across 50+ countries with regulatory-first execution.
• Orphan and Niche Therapeutic APIs Specialized APIs targeting rare diseases, CNS disorders, and metabolic conditions, developed through the strategic partnership with Haleos Labs, with expected 5 to 7 new molecules annually.

Quantifiable outcome

• Surpassed USD 50 million in revenue
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Haleos LabscoreStrategic or Co-development PartnerMulti-year strategic partnership to accelerate development and GMP manufacturing of orphan-drug and niche-therapeutic APIs for regulated and semi-regulated markets. Collaboration covers end-to-end development including route scouting, process intensification, scale-up, validation and global supply. Expected to deliver 5 to 7 new molecules annually targeting rare diseases, CNS disorders and metabolic conditions, with regulatory filings across US, EU, Latin America, MENA and APAC markets. HRV Pharma combines its asset-light digital platform and commercial reach across over 50 countries with Haleos Labs' chemistry expertise and 25-year manufacturing legacy.
• cGMP-Certified Manufacturers NetworkcoreStrategic or Co-development PartnerNetwork of high-quality, activated cGMP certified manufacturers that HRV Pharma leverages through its asset-light model. These strategic partnerships enable the company to offer maximum flexibility and complete compliance ownership without infrastructure burden. The network of underutilized globally compliant production facilities across India is turned into high-performance supply chains.
• New Horizon Global Pharma (NHG Pharma)coreStrategic or Co-development PartnerPart of HRV Global LifeSciences Group, New Horizon Global Pharma handles international operations including New Horizon Pharma USA, New Horizon Pharma UAB, and New Horizon Pharma FZCO. The companies share branding, sustainability recognition (EcoVadis Bronze Medal), and coordinate global pharmaceutical operations.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Syngene International: Indian CRO/CDMO providing integrated discovery, development, and manufacturing services to global pharma. Comparable to HRV in contract pharma services and global B2B customer model.
• Aurobindo Pharma: Vertically integrated Indian pharmaceutical manufacturer with global API and formulation operations across regulated markets. Highly comparable to HRV in API portfolio and B2B pharma customer base, but operates owned manufacturing at materially larger scale.
• Piramal Pharma Solutions: Global CDMO offering API development, manufacturing, and formulation services. Comparable to HRV's planned CDMO and FDF ambitions, with materially larger scale and broader service portfolio.

Direct peers

• Granules India: Indian API and finished dosage form manufacturer serving global regulated and emerging markets. Comparable to HRV on API sourcing, formulation plans, and export-led B2B go-to-market.
• Laurus Labs: Indian API and CDMO with strong presence in regulated markets and a growing portfolio of niche and complex APIs. Comparable in API focus, R&D depth, and global commercial reach to HRV's product set.
• Divi's Laboratories: Leading Indian API manufacturer focused on custom synthesis and generics APIs for global pharma. Closely comparable to HRV's core API business, including regulated-market filings and contract manufacturing relationships.
• Shilpa Medicare: Indian manufacturer of APIs, intermediates, and formulations with regulated-market focus. Comparable to HRV in API manufacturing and B2B distribution to global pharma partners.
• Sai Life Sciences: Indian contract development and manufacturing organization (CDMO) offering API development and manufacturing services for innovator pharma. Comparable to HRV on contract services, R&D, and global pharma customer base.
• Suven Pharmaceuticals: Indian CDMO focused on niche APIs and custom synthesis for global pharma, including CNS-related therapeutic areas. Closely comparable to HRV's orphan/CNS/metabolic API focus and contract development model.

Others

• Pharmexcil (Pharmaceuticals Export Promotion Council of India) member exporters: Industry body representing Indian pharma exporters; serves as an aggregator and trade-enabling entity for companies like HRV that export APIs and formulations to regulated and semi-regulated markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hrv-global-lifesciences

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HRV Global LifeSciences